Dr. Ralph Schiess
Chief Science Officer and Interim Chief Executive Officer
Dr. Ralph Schiess has been Chief Science Officer since December 2023 and Interim Chief Executive Officer since January 2024. Dr. Schiess worked for 10 years in world-class academic institutions both in the US and Europe and gained over 10 years of experience in the diagnostic industry successfully developing products from scientific prototypes to commercial products. Dr. Schiess was CEO and co-founder of Proteomedix AG, a Swiss healthcare company with the mission to transform prostate cancer diagnosis, which was acquired by the Company in December 2023. Under his guidance, Proteomedix identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product, Proclarix, is a blood-based prostate cancer test panel and risk score currently available in Europe and exclusively out-licensed to LabCorp for the US. Proclarix was recently included in both the American and European Urology guidelines. Dr. Schiess received his M.S. from the University of Zurich, followed by an internship at the Institute of System Biology in Seattle. Thereafter, he received a doctorate from the Swiss Federal Institute of Technology.
Christian Bruehlmann
Chief Strategy Officer

Christian Bruehlmann has been Chief Strategy Officer since December 2023. He was CBO and co-founder of Proteomedix AG, a Swiss healthcare company whose mission is to transform prostate cancer diagnosis, which was acquired by the Company in December 2023. Mr. Bruehlmann gained 20 years of experience in public and private companies in the life sciences, information and communications (ICT) and financial industries. Being responsible for product management, business development, operations and finance, he was instrumental in Proteomedix’ development from inception to the market introduction of the lead product Proclarix, a blood based prostate cancer test panel and risk score currently available in Europe and exclusively out-licensed to LabCorp for the US. Previously, he worked for Swisscom, Switzerland's telecom market leader in several strategic and leadership roles in the area of digitalization. Mr. Bruehlmann received his Bachelor and Master in Business Administration from University of Zurich, Switzerland and completed executive professional trainings at the Babson College, USA and at the University of St. Gallen, Switzerland.

Karina M. Fedasz
Interim Chief Financial Officer

Karina M. Fedasz has been the Interim Chief Financial Officer since June 2024.  For more than two decades, Ms. Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions. She is a dynamic, data-driven executive with a bold, high-growth mindset. From January 2023 to June 2024, Ms. Fedasz worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker. From February 2022 to December 2022, Ms. Fedasz served as Head of Business Development for Evofem Biosciences, a Nasdaq-listed public biotech company developing innovative products for women’s health. From August 2019 to October 2021, Ms. Fedasz served in various positions of increasing responsibility, including Chief Financial Officer, at IDW Media Holdings, a micro-cap media company, where she managed the company’s initial public offering. From April 2018 to August 2019, Ms. Fedasz served as Chief Financial Officer of MOCEAN, an integrated agency for entertainment, gaming, and brands. Ms. Fedasz’s breadth of experience has seen her lead teams in media, technology, services, manufacturing, and education, and she has worked with companies whose clients and customers include Fortune 500 companies such as Netflix, Disney, Amazon, Apple, Activision, and EA. Ms. Fedasz received an MBA with an emphasis in finance from Columbia Business School and a BA from University California at Los Angeles (UCLA). She holds an inactive CPA in the state of California.